Results 11 to 20 of about 3,189,219 (271)
Iron Chelation Therapy in Myelodysplastic Syndromes [PDF]
Advances in Hematology, 2010 Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload.
Emanuela Messa +2 more
doaj +8 more sources
Importance of iron chelation therapy
Thalassemia Reports, 2011 It is necessary to remember that today patients have different options of chelation treatment, as desferrioxamine, deferiprone and deferasirox are available. However, a patient has to be compliant with treatments.
A. Varoğlu
doaj +3 more sources
Combined iron chelation therapy
Annals of the New York Academy of Sciences, 2010 Patients with thalassemia major accumulate body iron over time as a consequence of continuous red blood cell transfusions which cause hepatic, endocrine, and cardiac complications. Despite the availability of three iron chelators, some patients fail to respond adequately to monotherapy with any of them. Combination therapy, consisting in the use of two
Galanello Renzo +5 more
openaire +3 more sources
Challenges of Iron Chelation in Thalassemic Children
Thalassemia ReportsThalassemia treatment still relies on supportive care, mainly including blood transfusion and iron chelation therapy. Iron chelation is considered the main factor responsible for the marked improvement in survival rates of thalassemic patients ...
Alkistis Adramerina, Marina Economou
doaj +2 more sources
Iron overload is a serious complication associated with transfusion-dependent anemias and anemias characterized by ineffective erythropoiesis. Iron accumulation is toxic to many tissues, causing heart failure, cirrhosis, liver cancer, growth retardation, and multiple endocrine abnormalities.Chelation therapy aims to balance the rate of iron ...
Cappellini, Maria Domenica +3 more
openaire +3 more sources
IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES
Mediterranean Journal of Hematology and Infectious Diseases, 2009 Transfusional hemosiderosis is a frequent complication in patients with transfusion dependent chronic diseases such as thalassemias and severe type of sickle cell diseases.
Paolo Cianciulli
doaj +3 more sources
Chelator-facilitated removal of iron from transferrin: Relevance to combined chelation therapy [PDF]
, 2008 Current iron chelation therapy consists primarily of DFO (desferrioxamine), which has to be administered via intravenous infusion, together with deferiprone and deferasirox, which are orally-active chelators.
Evans, PJ +3 more
core +8 more sources
Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome [PDF]
Advances in Hematology, 2010 Iron chelation therapy is often used to treat iron overload in patients requiring transfusion of red blood cells (RBC). A 76-year-old man with MDS type refractory cytopenia with multilineage dysplasia, intermediate-1 IPSS risk, was referred when he ...
Maha A. Badawi +3 more
doaj +2 more sources
Iron Chelation Therapy in the Context of the Latest Iron Science
Seminars in Hematology, 2007 Iron chelation therapy (ICT) has been available since 1963, when the current reference standard chelator deferoxamine (DFO) was introduced for the clinical treatment of iron overload. DFO, along with our improved knowledge of the management of iron overload, has since greatly reduced the morbidity of patients with thalassemia and markedly improved ...
Kattamis, Antonis
core +4 more sources
Haematologica, 2023 CALYPSO (clinicaltrials gov. Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron ...
Ali T. Taher +8 more
doaj +1 more source